NVCR

NovoCure Ltd

Nasdaq · Surgical & Medical Instruments & Apparatus · CIK 0001645113
$17.78 +0.40% $2.1B
Insider Selling Cluster (8 insiders)High Impact Filing (7/10)
Vol
Market Cap$2.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (77%)
Insider Activity0B / 17S
Insider Net $-$2.0M
SEC Reports9
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·CIK 0001645113·Prev Close $17.71

Recent Activity

Jun 5, 2026 SEC
NovoCure held its 2026 annual general meeting on June 3, 2026, re-electing all 11 director nominees and approving the Am
8-K — Impact 4/10
Jun 5, 2026 SEC
Seven NovoCure directors sold identical blocks of 2,945 shares each at $15.77 on June 2, 2026, totaling $325K in open-ma
CLUSTER — Impact 2/10
Jun 4, 2026 Insider
Leonard Frank X sold 34,273 shares
Chief Executive Officer @ $17.93 ($614.6K)
Jun 3, 2026 SEC
Seven NovoCure directors sold identical blocks of 2,945 shares each at $15.77 on June 2, 2026, for a total of $325K. The
CLUSTER — Impact 2/10
Jun 3, 2026 Insider
Ocean Allyson J was granted 16,999 shares
Director
Jun 3, 2026 Insider
LEUNG GABRIEL was granted 16,999 shares
Director
May 18, 2026 short_volume
Short Volume: NVCR — 56.6% short (0.3M / 0.5M)
Short: 295,472 | Exempt: 0 | TRF Vol: 521,680 | Short Ratio: 56.6% | Off-exchange volume (dark pool

Price Targets

$26.29 +47.8% upside Strong Buy
Current $17.78 Low $17.00 Median $27.00 High $48.00 7 analysts
$17.00 $48.00

Analyst Ratings

Buy77% buy · 13 analysts
4Strong Buy
6Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 4, 2026 Wells Fargo MAINTAIN Equal-Weight → Equal-Weight
May 1, 2026 Evercore ISI Group MAINTAIN Outperform → Outperform
Apr 16, 2026 Wedbush REITERATE Neutral → Neutral
Feb 26, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Feb 12, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.33 ▲ +9.7% $-0.40 — $-0.23 8% YoY 7
Next Q $-0.33 ▲ +2.6% $-0.40 — $-0.22 1% YoY 7
Current FY $-1.59 ▼ -3.8% $-1.78 — $-1.26 -31% YoY 7
Next FY $-1.17 $-1.49 — $-0.86 27% YoY 7

Latest Reports

NEUTRAL 8-K 4/10
NovoCure held its 2026 annual general meeting on June 3, 2026, re-electing all 11 director nominees and approving the Am
Jun 5, 2026
NEUTRAL CLUSTER 2/10
Seven NovoCure directors sold identical blocks of 2,945 shares each at $15.77 on June 2, 2026, totaling $325K in open-ma
Jun 5, 2026

Recent Insider Trades

DateInsiderTypeValue
Jun 4, 2026Leonard FrankSELL$614.6K
Jun 3, 2026Ocean AllysonA$0.00
Jun 3, 2026LEUNG GABRIELA$0.00
Jun 3, 2026Madden MartinA$0.00
Jun 3, 2026Hung DavidA$0.00
∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

17 unique insiders with 50 transactions. Net insider value: -$2.0M ($0.00 bought, $2.0M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 4, 2026Leonard Frank XChief Executive OfficerSELL34,273$17.93$614.6K
Jun 3, 2026Ocean Allyson JDirectorAWARD16,999——
Jun 3, 2026LEUNG GABRIELDirectorAWARD16,999——
Jun 3, 2026Madden Martin J.DirectorAWARD11,610——
Jun 3, 2026Hung DavidDirectorAWARD16,999——
Jun 3, 2026Stafford KristinDirectorAWARD16,999——
Jun 3, 2026Madden Martin J.DirectorAWARD16,999——
Jun 3, 2026HILLEMAN JERYL LDirectorAWARD11,610——
Jun 3, 2026VERNON W ANTHONYDirectorAWARD11,610——
Jun 3, 2026Scannell Timothy JDirectorAWARD16,999——
Jun 3, 2026HILLEMAN JERYL LDirectorAWARD16,999——
Jun 3, 2026Stafford KristinDirectorAWARD11,610——
Jun 3, 2026VERNON W ANTHONYDirectorAWARD16,999——
Jun 3, 2026Ocean Allyson JDirectorAWARD11,610——
Jun 3, 2026LEUNG GABRIELDirectorAWARD11,610——
Jun 3, 2026Hung DavidDirectorAWARD11,610——
Jun 3, 2026Scannell Timothy JDirectorAWARD11,610——
Jun 2, 2026VERNON W ANTHONYDirectorSELL2,945$15.77$46.4K
Jun 2, 2026Hung DavidDirectorSELL2,945$15.77$46.4K
Jun 2, 2026Ocean Allyson JDirectorSELL2,945$15.77$46.4K
Jun 2, 2026Stafford KristinDirectorSELL2,945$15.77$46.4K
Jun 2, 2026Scannell Timothy JDirectorSELL2,945$15.77$46.4K
Jun 2, 2026HILLEMAN JERYL LDirectorSELL2,945$15.77$46.4K
Jun 2, 2026LEUNG GABRIELDirectorSELL2,945$15.77$46.4K
Apr 28, 2026VERNON W ANTHONYDirectorEXERCISE21,500$11.39$244.9K
Mar 5, 2026Paravasthu MukundChief Operating OfficerSELL43,246$13.77$595.7K
Mar 4, 2026Leonard Frank XChief Executive OfficerSELL5,607$13.31$74.6K
Mar 4, 2026Weinberg UriChf Medical and Innovation OfrSELL6,412$13.31$85.3K
Mar 4, 2026Cordova AshleyFormer Chief Executive OfficerTAX W/H17,638$13.30$234.6K
Mar 4, 2026Leupin NicolasFormer Chief Medical OfficerSELL1,100$13.31$14.6K
Mar 4, 2026Brackmann ChristophChief Financial OfficerSELL6,412$13.31$85.3K
Mar 4, 2026Paravasthu MukundChief Operating OfficerSELL5,377$13.31$71.5K
Mar 4, 2026Puri Michal NathChief Human Resources OfficerSELL1,100$13.31$14.6K
Mar 3, 2026Ben Arye BarakGeneral CounselAWARD50,125——
Mar 3, 2026Ben Arye BarakGeneral CounselAWARD73,340——
Mar 3, 2026Weinberg UriChf Medical and Innovation OfrAWARD73,340——
Mar 3, 2026Puri Michal NathChief Human Resources OfficerAWARD40,100——
Mar 3, 2026Leonard Frank XChief Executive OfficerAWARD150,000——
Mar 3, 2026DOYLE WILLIAM FExecutive ChairmanAWARD200,000——
Mar 3, 2026DOYLE WILLIAM FExecutive ChairmanAWARD258,445——
Mar 3, 2026Brackmann ChristophChief Financial OfficerAWARD80,674——
Mar 3, 2026Brackmann ChristophChief Financial OfficerAWARD55,137——
Mar 3, 2026Paravasthu MukundChief Operating OfficerAWARD7,518——
Mar 3, 2026Paravasthu MukundChief Operating OfficerAWARD45,112——
Mar 3, 2026Puri Michal NathChief Human Resources OfficerAWARD58,672——
Mar 3, 2026Leonard Frank XChief Executive OfficerAWARD216,388——
Mar 3, 2026Weinberg UriChf Medical and Innovation OfrAWARD50,125——
Mar 2, 2026Weinberg UriChf Medical and Innovation OfrSELL3,272$13.33$43.6K
Mar 2, 2026Leonard Frank XChief Executive OfficerSELL7,232$13.49$97.6K
Mar 2, 2026Cordova AshleyFormer Chief Executive OfficerTAX W/H2,410$13.67$32.9K
9 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 7 neutral. Avg impact: 3.9/10.
NEUTRAL 8-K 4/10
NovoCure held its 2026 annual general meeting on June 3, 2026, re-electing all 11 director nominees
Jun 5, 2026
NEUTRAL CLUSTER 2/10
Seven NovoCure directors sold identical blocks of 2,945 shares each at $15.77 on June 2, 2026, total
Jun 5, 2026
NEUTRAL CLUSTER 2/10
Seven NovoCure directors sold identical blocks of 2,945 shares each at $15.77 on June 2, 2026, for a
Jun 3, 2026
NEUTRAL DEFA14A 3/10
NovoCure's DEFA14A filing is a definitive proxy statement for its 2026 Annual Meeting, where shareho
Apr 20, 2026
NEUTRAL CLUSTER 4/10
Multiple NovoCure executives, including CEO Leonard Frank X and CMO Weinberg Uri, conducted open-mar
Mar 5, 2026
BEARISH CLUSTER 5/10
Multiple NovoCure executives, including CEO Leonard Frank X and Chief Medical Officer Uri Weinberg,
Mar 3, 2026
NEUTRAL CLUSTER 3/10
Two NovoCure insiders, including C-suite executives, sold shares in open-market transactions totalin
Mar 3, 2026
MIXED 8-K 7/10
NovoCure reported 8% year-over-year revenue growth for Q4 and full year 2025, driven by increased ac
Feb 26, 2026
NEUTRAL 8-K 5/10
NovoCure announced that CMS rescinded the prior revocation of its Medicare billing privileges, reins
Feb 24, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Buy (77% buy). Based on 13 analysts: 4 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$26.29 mean target +47.8% upside Strong Buy (1.71)
$17.00 Low $48.00 High
MetricValue
Current Price$17.78
Target Low$17.00
Target Mean$26.29
Target Median$27.00
Target High$48.00
# Analysts7
RecommendationStrong Buy (1.71)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.33 $-0.40 $-0.23 7.5% +9.7% 5↑ 2↓ $0.2B 8.8% 7
Next Q
2026-09-30
 $-0.33 $-0.40 $-0.22 0.9% +2.6% 3↑ 2↓ $0.2B 5.5% 7
Current FY
2026-12-31
 $-1.59 $-1.78 $-1.26 -30.7% -3.8% 2↑ 4↓ $0.7B 7.4% 7
Next FY
2027-12-31
 $-1.17 $-1.49 $-0.86 26.5% -0.5% 3↑ 4↓ $0.8B 10.4% 7

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.333
7d ago$-0.333
30d ago$-0.369+0.036
60d ago$-0.369+0.036
90d ago$-0.403+0.070
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 4, 2026 Wells Fargo MAINTAIN Equal-Weight Equal-Weight
May 1, 2026 Evercore ISI Group MAINTAIN Outperform Outperform
Apr 16, 2026 Wedbush REITERATE Neutral Neutral
Feb 26, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Feb 12, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Jan 15, 2026 Wedbush REITERATE Neutral Neutral
Jan 13, 2026 HC Wainwright & Co. MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264630077%
May 1, 20264630077%
Apr 1, 20264630077%
Mar 1, 20264630077%
Feb 1, 20264630077%
Jan 1, 20264630077%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 2, 2026
Clinical Trial
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase Phase 2 — TERMINATED
May 18, 2026
short_volume
Short Volume: NVCR — 56.6% short (0.3M / 0.5M)
Short: 295,472 | Exempt: 0 | TRF Vol: 521,680 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
Clinical Trial
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
Phase Phase 2 — COMPLETED
Apr 30, 2026
earnings_calendar
NVCR Q1 2026 Earnings Scheduled — 2026-04-30
Apr 20, 2026
earnings_calendar
NVCR Q1 2026 Earnings Scheduled — 2026-04-20
Mar 30, 2026
short_volume
Short Volume: NVCR — 61.3% short (0.3M / 0.5M)
Short: 306,851 | Exempt: 1,143 | TRF Vol: 500,938 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
Feb 26, 2026
earnings_calendar
NVCR Q4 2025 Earnings Before Market Open — 2026-02-26